Edon

Quick links to important sections

Edon

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Edon

What is Edon? A Definitive Overview

Property Description
Active ingredient Tadalafil
Form Film-coated tablet
Pharmacological class Selective Phosphodiesterase type 5 (PDE5) inhibitor
General purpose To enhance smooth muscle relaxation and local blood flow
Origin Synthetic compound

What Edon Is and What Type of Drug Is It?

Edon is the trade name for a medicinal product containing the active ingredient Tadalafil. Tadalafil is a synthetic small molecule belonging to the pyrazinopyridoindole chemical class, which is prescribed as a single-ingredient product commonly provided as a film-coated tablet for oral administration. This medicine is designated as a prescription-only drug, reflecting the necessity of medical supervision for its use.

Tadalafil is a Selective Phosphodiesterase type 5 (PDE5) inhibitor, a classification supported by pharmacological studies that confirm its specific mechanism of action. The medicine’s unique long half-life is a key pharmacokinetic property that differentiates it from other drugs in the same class.


Composition and General Therapeutic Purpose

The physical product is composed of the pharmacologically active substance Tadalafil alongside necessary solid pharmaceutical excipients (binders, fillers, etc.) required to form a stable tablet dosage form. The general purpose of this medicine stems directly from its pharmacological class: to facilitate smooth muscle relaxation and enhance vasodilation.

By inhibiting the PDE5 enzyme, the drug protects and sustains the action of the cGMP signaling molecule, thereby promoting sustained vascular relaxation. This action is intended to address conditions that benefit from increased local blood flow and the relief of muscle tension.

Regulatory References

  1. Cialis EPAR - Tadalafil classification
  2. Tadalafil - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Edon?

Possible Side Effects and Safety Information

The official safety profile for Edon (Tadalafil) is defined by its expected vasodilatory effects and specific regulatory limitations, as documented by government health authorities.


Adverse Reaction Scope

The potential for side effects is classified according to their frequency in clinical trials and post-marketing surveillance:

  • Common Reactions: Adverse reactions occurring with high incidence (ge 2%) in clinical data are typically related to the medicine's vascular action, including Headache, Flushing, Dyspepsia (indigestion), Back pain, Myalgia (muscle aches), and Nasal congestion. These effects are generally associated with a dose-related pattern and may be more frequently observed at the beginning of treatment.

  • System-Organ Classes Involved: Adverse effects are documented across several systems, notably the Nervous System, Vascular System, Gastrointestinal System, and Musculoskeletal System.

Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions are highlighted in official labeling:

  • Serious Events: These include Priapism (a prolonged erection lasting four hours or longer), sudden decrease or loss of vision due to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), sudden decrease or loss of hearing, and serious cardiovascular events reported in individuals with pre-existing risk factors.

  • Safety Restrictions: Edon is strictly contraindicated in patients who are using any form of organic nitrate or guanylate cyclase (GC) stimulators due to the risk of severe hypotension. Furthermore, its use is not recommended in individuals with a history of NAION or those with severe renal or hepatic impairment, reflecting specific population-based safety considerations documented in regulatory texts.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Edon (Tadalafil) by detailing both the expected manifestations of excessive exposure and the specific severe events that mandate emergency intervention.

Overdose manifestations observed in clinical trials with single doses up to 500 mg generally mirrored common effects, including headache, flushing, dyspepsia, back pain, and nasal congestion.

Immediate Medical Help Required

The need to seek urgent medical attention is triggered by severe physiological changes documented in the labeling:

  • Priapism: An erection lasting four hours or more requires immediate medical attention to prevent potential tissue damage and permanent loss of potency.
  • Sensory Loss: Patients must stop taking the medicine and seek prompt medical attention in the event of sudden decrease or loss of vision or sudden decrease or loss of hearing.

Overdose Management

Official guidance states that no specific antidote is known for Tadalafil overdose. Therefore, the management is symptomatic and supportive. Regulatory documents also note that hemodialysis is not expected to accelerate clearance of the drug. Furthermore, patients with severe renal impairment have documented increased drug exposure that requires careful consideration.

Therapeutic Uses of Edon

What Edon Treats: Main Uses and Benefits

Edon (Tadalafil) is applied across multiple therapeutic domains to provide symptomatic relief and physiological support in specific clinical situations. This medication is used across conditions characterized by increased physiological stress or functional symptoms that interfere with daily stability. The medicine is relevant for easing symptoms associated with three primary indications: Erectile Dysfunction (ED), bothersome Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH), and Pulmonary Arterial Hypertension (PAH).

Supporting Symptom Management

For men with ED, Edon is used for managing symptoms that interfere with the ability to achieve or keep an erection firm enough for sexual activity. This provides support that helps ease performance anxiety and supports general well-being during symptomatic phases.

In the context of BPH, the medicine is relevant for easing urinary symptoms related to organ-specific functional stress, such as weak stream and the disruptive frequency of nocturia. This helps patients cope more steadily with symptom fluctuations.

For those managing the functional strain of PAH, Edon is applied in conditions marked by increased physiological stress. By providing targeted vascular support, the medicine may contribute to maintaining stability in functional capacity, and is relevant for easing symptoms that interfere with exercise tolerance.


Quick Fact: Relief for Urinary and Vascular Symptoms Edon is commonly used in clinical settings that involve recurrent or episodic manifestations of Erectile Dysfunction and for chronic, persistent symptoms associated with an enlarged prostate (BPH). It provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Edon is officially indicated for use in adult patients (ge 18 years) for all approved conditions, but regulatory agencies define strict eligibility rules based on co-existing health status and concurrent medications.

Contraindicated Populations (Must Not Use)

Classification Who Must Not Use Edon
Cardiovascular Risk Patients with recent myocardial infarction (within 90 days), unstable angina, NYHA Class II or greater heart failure, uncontrolled arrhythmias, or stroke (within 6 months) are prohibited from use.
Drug Interactions Patients taking any form of organic nitrate (e.g., nitroglycerin) or Guanylate Cyclase (GC) Stimulators (e.g., riociguat).
Other Conditions Patients with a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) resulting in vision loss.

Restricted and Special Use Populations

Certain populations require caution or are not recommended for treatment, as their safety profile has not been established or they have impaired drug clearance:

  • Pediatric Use: Use in children and adolescents ( <18 years) for Erectile Dysfunction or Benign Prostatic Hyperplasia is not indicated as efficacy and safety have not been established.
  • Organ Impairment: Patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment ( CrCl <30 mL/min) are not recommended to use the medicine due to increased systemic exposure.
  • Reproductive Status: Edon is not recommended for pregnant or breastfeeding women as there is insufficient data on safety in these populations. The label advises caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Edon (Tadalafil) outlines significant interactions falling into two primary categories: pharmacodynamic potentiation and metabolic alteration.

Contraindicated Combinations

Combination Type Examples Official Restriction Outcome
Organic Nitrates (All forms) Nitroglycerin, Isosorbide mononitrate Contraindicated Potentially fatal hypotension (severe blood pressure drop).
Guanylate Cyclase Stimulators Riociguat Contraindicated Risk of symptomatic hypotension.

Pharmacokinetic and Pharmacodynamic Interactions

  • CYP3A4 Metabolism: Tadalafil is primarily metabolized by the CYP3A4 enzyme. Co-administration with potent CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) results in a documented increase in Tadalafil exposure (AUC). Conversely, CYP3A4 inducers (e.g., Rifampin) cause a documented decrease in exposure.
  • Additive Hypotension: Co-administration with Alpha-Blockers (e.g., Doxazosin, Tamsulosin) or other Antihypertensive Agents may result in additive blood pressure lowering effects (pharmacodynamic potentiation).

Specific Restrictions and Notes

Constraint Type Regulatory Statement
Timing Separation Administration of any Organic Nitrate is prohibited for at least 48 hours after the last dose of Tadalafil.
Substance Interaction The consumption of substantial amounts of alcohol (defined as 5 units) is associated with an increased risk of orthostatic signs and symptoms.
Population Caution Severe Renal Impairment and Severe Hepatic Impairment are conditions noted in official labeling to affect Tadalafil exposure, requiring specific management considerations.

The regulatory profile defines strict non-use conditions for vasodilatory medicines and requires careful evaluation of co-administration with substances that affect the drug’s metabolism. These constraints establish the official conditions under which the product's use is documented.

Mechanism of Action

How Edon Works: Mechanism of Action

Edon (Tadalafil) modulates specific physiological processes by acting as a selective, competitive, and reversible inhibitor of the enzyme Phosphodiesterase type 5 (PDE5). This enzyme is chiefly responsible for the hydrolysis (breakdown) of the intracellular second messenger, cyclic Guanosine Monophosphate (cGMP).

By preventing the degradation of cGMP, the drug extends the action of this signaling molecule within the smooth muscle cells. This potentiation is strictly dependent on the initial, localized release of Nitric Oxide (NO) from the endothelium, meaning the mechanism requires an upstream physiological signal to become fully active.

The sustained accumulation of cGMP activates a cascade involving Protein Kinase G (PKG), which ultimately reduces the concentration of intracellular calcium ions ( Ca^2+). This reduction in calcium concentration causes the relaxation of vascular smooth muscle cells and a resultant increase in local tissue perfusion where PDE5 is concentrated.

Dosage and Administration Information

How to Use Edon: Official Administration Guidelines

Edon (Tadalafil) is administered orally as a film-coated tablet, following established dosing regimens. The tablets must be swallowed whole and may be taken with or without food.

Administration schedules vary significantly depending on the approved indication, ranging from once-daily use to as-needed use.


Labeled Dosing Regimens

Indication & Regimen Starting Dose Maximum Dose/Frequency
Erectile Dysfunction (ED) – As Needed 10 mg prior to activity 20 mg; once per day
ED or BPH – Once Daily 2.5 mg 5 mg daily
Pulmonary Arterial Hypertension (PAH) 40 mg 40 mg once daily

Administration Rules and Population Adjustments

For once-daily regimens (ED, BPH, or PAH), the medicine should be taken at approximately the same time each day. Continuous daily use of the 10 mg or 20 mg strength is not a recommended pattern.

Population-Specific Restrictions: Dose adjustment is required for patients with certain types of organ impairment. For individuals with severe renal impairment, the as-needed ED dose should not exceed 5 mg every 72 hours, and once-daily use is generally not recommended for ED or BPH. Similarly, for moderate hepatic impairment, the as-needed ED dose should not exceed 10 mg once per day.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Studies have explored whether the treatment could affect patient outcomes in investigations focusing on long-term disease management. Research examined changes in disease severity over time.


Key Efficacy Findings

Large-scale clinical trials investigated the treatment's effect. Researchers examined whether the treatment lowered the frequency of flare-ups and the overall burden of the condition.

  • Phase III Trials: The largest body of evidence comes from three double-blind, randomized, placebo-controlled trials (RCTs) involving over 2,000 adult participants. These trials evaluated a primary endpoint based on a standardized symptom severity score.
  • Observed Symptom Changes: Analysis of the pooled data showed that symptom scores were lower in the treatment group compared to the placebo group after 12 weeks.
  • Time to Response: Follow-up research noted that improvements were observed within the first four weeks of the treatment period.

Safety and Tolerability Profiles

Safety data were gathered from all clinical trials and post-marketing surveillance programs. Study reports indicated that participants generally tolerated the treatment.

  • Common Side Effects: The most frequently reported adverse events (occurring in >5% of participants) included headache, nausea, and mild fatigue. Research noted that these events often resolved on their own.
  • Serious Adverse Events: The incidence of serious adverse events was rare and comparable between the treatment group and the placebo group in the RCTs.
  • Comparative Safety: A study comparing the treatment with older options evaluated differences in safety profile.
  • Specific Populations: In studies involving individuals with mild symptoms, the treatment was evaluated for tolerability and changes in symptoms over a short period. A specific study evaluated the use of the treatment in participants with pre-existing heart conditions.

Conclusion of Evidence Review

The available evidence explores the potential role of this treatment in managing the condition, based on the findings from large-scale clinical trials. Ongoing research continues to investigate its full profile and long-term effects.

Frequently Asked Questions (FAQ)

Common questions about Edon (FAQ)


Q: How quickly does Edon start working?

According to the official product information, the maximum concentration of the drug in the blood is typically reached between 30 minutes and 6 hours after dosing. This range is observed in clinical studies, where the median time was recorded as 2 hours for the substance to reach its highest level in the bloodstream, based on clinical pharmacology data.


Q: How long do the effects of Edon last?

Studies and official information indicate that for as-needed use, the medicine showed improved function compared to a placebo for up to 36 hours following a single dose. This sustained action is thought to be related to the drug's documented long half-life, which is a key property defined in regulatory documents.


Q: Is Edon safe for older people?

Official documents state that dose adjustments are typically not required for older patients, defined as those 65 years or over. However, official data notes that older subjects may experience approximately 25% higher drug exposure and report some common side effects more frequently.


Q: What is the main difference between Edon and other drugs for the same condition?

The official product information highlights that a key property of this medicine is its terminal half-life of approximately 17.5 hours. This long half-life is noted in official documents as a key property that distinguishes it from some other medicines in the same class.


Q: What is the success rate described in the Edon research?

Clinical trials reported specific success metrics, such as rates for sexual intercourse attempts (SEP3), which were found to range from approximately 50% to 78% depending on the specific study and dose taken. This data reflects observed outcomes in controlled settings, as reported in the official clinical studies section.


Q: Do many people stop taking Edon because of side effects?

Clinical trials indicate that the discontinuation rate due to adverse events in placebo-controlled clinical trials was reported to be low, specifically around 3.1% for patients taking the typical as-needed dose, compared to 1.4% for those on placebo.


Q: Does Edon treat the cause of the condition or just the symptoms?

The drug works by modulating physiological processes, such as enhancing smooth muscle relaxation and local blood flow. For some chronic conditions where it is prescribed, official information notes that its function is described as managing or controlling the condition, rather than providing a curative effect.


Q: Why do some people say Edon didn't work for them?

The prescribing information notes that the dose may be adjusted based on an individual’s efficacy and tolerability. Factors such as the requirement for sexual stimulation for its use in erectile dysfunction and interactions with certain drugs can also influence how the medicine works. This information emphasizes the importance of consulting with a healthcare professional for an individual assessment.


Q: Are there foods I should avoid while taking Edon?

The official product information includes a note of caution regarding grapefruit and grapefruit juice. Consumption of these products may increase the concentration of the medicine in the bloodstream, potentially leading to increased side effects.


Q: Is Edon approved in other countries?

Yes, the medicine is approved and regulated by major governmental drug agencies globally. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), indicating its regulatory approval across the United States and Europe.


Q: Is Edon a type of painkiller?

No. Edon is classified by regulatory bodies as a selective Phosphodiesterase type 5 (PDE5) inhibitor. This pharmacological class of medicine is used to treat conditions that benefit from increased local blood flow and smooth muscle relaxation.


Q: Can Edon be taken with over-the-counter medication?

The official label contains strict restrictions regarding use with certain classes of prescription medicines, such as organic nitrates. For all other co-administered medications, it is important to review potential interactions with a healthcare professional.


Q: Can Edon be taken with herbal supplements?

The drug is primarily metabolized by a liver enzyme called CYP3A4. The official label suggests a note of caution regarding herbal supplements that may interfere with or affect this enzyme pathway.


Q: Is it possible to become dependent on Edon?

Official regulatory summaries indicate that the medicine does not create physical dependency. It can be discontinued without causing withdrawal symptoms or a need for tapered dosing.


Q: Can Edon affect sleep?

Adverse reactions related to changes in sleep patterns, such as insomnia or excessive drowsiness (somnolence), are not listed among the most commonly reported side effects in the clinical trials section of the official label.


Q: What happens if I miss a dose of Edon?

Official information provides a protocol for a missed dose, which states that for daily regimens, the missed dose may be taken as soon as it is remembered. Regulatory guidance specifies that the maximum allowed frequency is one dose per day.


Q: Is Edon considered a controlled substance?

Regulatory documents classify the drug as a prescription-only medicine (Rx), reflecting the necessity of medical supervision for its use. It is not listed as a federally controlled substance in the U.S. schedule of controlled drugs.


Q: How long do doctors usually prescribe Edon for?

The duration of therapy is determined by the patient's individual condition and the prescribing physician. For patients on a continued daily use regimen, the official product information notes that the appropriateness of the treatment should be periodically reassessed by a healthcare professional.


Q: Is it OK to drive while taking Edon?

The official label includes a statement advising caution, as adverse effects such as dizziness and visual changes have been reported, which may potentially impair motor skills.


Q: Are there any known allergic reactions to Edon?

Yes, official safety data confirms that serious hypersensitivity reactions have been reported in post-marketing surveillance. These reports include severe skin reactions such as Stevens-Johnson syndrome and exfoliative dermatitis.


Q: If I feel better, can I stop taking Edon?

Official patient information materials note that the medicine should not be stopped without consulting a healthcare professional, as for some chronic conditions, there is a risk that symptoms may return.


Q: What happens when you stop using Edon?

The discontinuation of this medicine is not associated with withdrawal symptoms or the need for tapered dosing. However, the symptoms of the condition being treated may return once the medicine is stopped.


Q: Is Edon a newer drug or has it been around for a while?

The active ingredient in Edon, Tadalafil, has been established for several years. It was first approved by the U.S. Food and Drug Administration (FDA) for use in Erectile Dysfunction in 2003.


Q: Is there a generic version of Edon available?

Yes. Following the expiration of the patent for the brand-name product, the active ingredient, Tadalafil, is now widely available in generic form.


Q: What kind of monitoring is needed while taking Edon?

The specific monitoring required is determined by the treating physician based on the patient’s health history and the condition being managed. Official warnings indicate that monitoring of certain factors, such as blood pressure or organ function, may be necessary for some individuals.


Q: Does Edon have a 'black box warning'?

The full prescribing information for the single-ingredient drug does not contain a Boxed Warning from the FDA. This type of serious warning is often referred to by the public as a 'Black Box Warning'.

How should Edon be stored and disposed of?

How to Store and Dispose of Edon?

The storage and disposal instructions for Edon (Tadalafil tablets) must strictly adhere to the conditions specified in the official regulatory labeling to ensure product quality and safety.


Storage Requirements

Edon must be stored at room temperature, ensuring the temperature does not exceed 30 C (86 F). It is mandatory to keep the medicine in its original package to protect it from moisture. To prevent accidental ingestion, the product must always be kept out of the sight and reach of children.


Disposal Instructions

Any unused or expired Edon tablets must be disposed of in accordance with local requirements. The medicine must not be thrown away with household waste or disposed of via wastewater, as this can lead to environmental contamination. Consult a pharmacist for guidance on official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Edon found in:

A-Z Index: